Malet A, Lluch M, Valero A, Amat P
Al-lergo Centre, Barcelona, Spain.
Allergol Immunopathol (Madr). 1993 Jan-Feb;21(1):7-10.
This is the second in a series of studies carried out on a group of 26 patients undergoing immunotherapy (IT) (9). The objective of this paper was to determine a new subclass of specific IgG, IgG1, so as to achieve comparable results with the previous study on IgG4. All patients in the study group were suffering from respiratory diseases and were all sensitized to Dermatophagoides pteronyssinus (DPT). They were subjected to IT for a period of 36 months. A 6 monthly control on the levels of anti-DPT specific IgE, anti-DPT specific IgG1 and anti-DPT specific IgG4 was done. Our results showed a level drop in anti-DPT specific IgE after 12 months of immunotherapy (p < 0.001) which was maintained in the 6 monthly controls which followed levels of anti-DPT (p < 0.01). Levels of anti-DPT specific IgG1 (p < 0.05) were lowered following 30 months of IT and were maintained till the end of treatment. The levels of anti-DPT specific IgG4 showed a level increase (p < 0.05) between 6 and 24 months of IT. The anti-DPT specific IgG4 level after 36 months of immunotherapy were lower than those obtained after 24 months of immunotherapy and were of no statistical significance. These values were statistically significant, however, when compared with the levels obtained prior to IT (p < 0.05). The IgG4/IgG1 ratio showed a gradual increase and reached extreme values after 24 months of IT (p < 0.05). There was no relationship between these values and the clinical evolution of each patient.
这是对一组26名接受免疫疗法(IT)的患者进行的系列研究中的第二项(9)。本文的目的是确定特异性IgG的一个新亚类IgG1,以便获得与先前关于IgG4的研究相当的结果。研究组中的所有患者均患有呼吸系统疾病,且均对粉尘螨(DPT)致敏。他们接受了36个月的免疫疗法。每6个月对针对DPT的特异性IgE、针对DPT的特异性IgG1和针对DPT的特异性IgG4水平进行一次检测。我们的结果显示,免疫疗法12个月后针对DPT的特异性IgE水平下降(p<0.001),在随后每6个月的检测中该水平一直维持,针对DPT的水平(p<0.01)。免疫疗法30个月后,针对DPT的特异性IgG1水平降低(p<0.05),并维持到治疗结束。针对DPT的特异性IgG4水平在免疫疗法的6至24个月之间升高(p<0.05)。免疫疗法36个月后的针对DPT的特异性IgG4水平低于免疫疗法24个月后获得的水平,且无统计学意义。然而,与免疫疗法之前获得的水平相比,这些值具有统计学意义(p<0.05)。IgG4/IgG1比值逐渐升高,在免疫疗法24个月后达到极值(p<0.05)。这些值与每位患者的临床进展之间没有关系。